Jefferies

Pharma

M&A surge triggers high expectations for 2026

A blitz of biopharma activity at the end of March indicates that 2026 will be a prime year for M&A and that the surge seen in Q4 was not a false alarm.

Kevin Dunleavy Apr 6, 2026 5:00am

Novo's Wegovy supply woes could soon be resolved: analysts

Jan 27, 2022 9:20am

GlaxoSmithKline GSK House in Brentford UK

GSK rebuffs $68B buyout bid, but Unilever is undeterred

Jan 18, 2022 7:55am

Only $300K for Biogen's Aduhelm in Q3, far below consensus

Oct 20, 2021 10:23am

GSK's Shingrix rebound has yet to materialize, analysts say

Sep 16, 2021 9:32am

Apellis' Empaveli could reap $4B in race against Alexion drugs

Aug 19, 2021 11:50am